Skip to main content
RNTX logo

Rein Therapeutics Inc.

RNTXNASDAQHealthcareBiotechnology

$0.59Today:- (-)1Y −48.52%

As of Oct 16, 2026 close

Market cap
$53.86M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.54$2.18
Volume (live)
-
Avg. volume (3M)
434.87K

Rein Therapeutics (RNTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Mar 31, 2026), Rein Therapeutics used $19.36M of cash in operating activities. Free cash flow was −$19.36M.

Rein Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Rein Therapeutics Inc. (RNTX) - Annual data in millions USD
BreakdownFY 2025FY 2025FY 2024FY 2024FY 2023FY 2023FY 2022FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingMar 2026Dec 2025Mar 2025Dec 2024Mar 2024Dec 2023Mar 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-49.87-49.87-62.88-62.88-15.73-15.73-27.33-27.33-26.16-21.16-29.37-31.55
Depreciation & Amortization0.000.000.060.060.120.120.170.170.120.160.160.22
Deferred Income Tax-0.71-0.00-0.00-0.00-0.000.000.000.00
Stock Based Compensation2.222.221.121.121.191.192.082.082.261.892.123.28
Change in Working Capital-0.87-0.872.412.41-5.38-5.380.420.420.24-1.280.850.38
Change in Accounts Payable3.073.07-0.28-0.28-4.98-4.980.510.51-0.390.12-0.280.13
Change in Other Working Capital-3.930.452.691.00-0.40-0.02-0.091.48-0.38-1.401.130.25
Other Operating Activities29.860.4537.0037.000.000.00-0.21-0.21-0.21-0.10-0.23-0.25
Net Cash from Operating Activities-19.36-19.36-22.29-22.29-19.81-19.81-24.87-24.87-23.75-20.48-26.47-27.93
Investing Activities
Capital Expenditures0.00-0.00-0.00-0.00--0.160.00-0.15-4.42
Acquisitions0.00-0.00--0.10-0.100.000.000.000.000.000.00
Purchases of Investments0.00-0.00-0.0016.25-21.85-21.85-73.586.21-27.24-31.19
Sales/Maturities of Investments0.00-0.00-16.2516.2548.3148.3137.7516.2424.5760.31
Other Investing Activities0.00-0.00-0.04-0.00-0.070.210.0029.11
Net Cash from Investing Activities0.00-0.00-16.2016.2026.4626.46-35.926.41-2.8124.69
Financing Activities
Debt Repayment0.00-0.00-0.00-0.00-0.000.390.002.47
Common Stock Issued9.763.4110.6510.650.0015.790.00-55.6615.4123.800.04
Other Financing Activities0.002.857.177.0315.7915.790.00--3.510.000.170.04
Net Cash from Financing Activities9.769.7617.8217.8215.7915.790.00-55.6615.8023.962.52
Summary
Effect of Forex Changes on Cash-0.04-0.040.00--0.06-0.060.00-0.000.000.000.00
Net Change in Cash-9.65-9.65-4.47-4.4712.1212.121.591.59-4.011.74-5.32-0.72
Cash at Beginning of Period12.8712.8717.3417.345.225.223.633.637.645.9011.2311.95
Cash at End of Period3.223.2212.8712.8717.3417.345.225.223.637.645.9011.23
Free Cash Flow-19.36-19.36-22.29-22.29-19.81-19.81-24.87-24.87-23.91-20.48-26.63-32.35

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rein Therapeutics Cash Flow

What is Rein Therapeutics's free cash flow?

Rein Therapeutics had negative free cash flow of $19.36M in fiscal 2025 (fiscal year ended Mar 31, 2026).

Does Rein Therapeutics pay dividends or buy back shares?

Rein Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition